Head-to-head evidence
insulin aspart vs insulin NPH
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
insulin aspart · NovoLog / Fiasp
Marketed by Novo Nordisk
NCT01467323 · Phase 3 · completed
The study randomly assigned 303 participants to biphasic insulin aspart or an active insulin comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
insulin NPH · Humulin N / Novolin N
Marketed by Eli Lilly and partners
NCT01562561 · Phase 3 · completed
The trial randomized 213 participants to repaglinide plus insulin NPH or insulin NPH alone, but it was open-label rather than blinded. Its primary endpoint, HbA1c, is a surrogate measure, and no primary-endpoint results are posted, so whether the comparison was favorable is unknown.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin aspart's landscape · insulin NPH's landscape